DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT05965908

CompletedPhase 3

Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome

Effect of Liraglutide on Different Parameters (Clinical , Metabolic and Hormonal) in Obese Women With Polycystic Ovary Syndrome

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

150

actual

Study population

Obesity / overweight, PCOS, Reproductive / infertility

Key I/E criterion

•Female

Primary endpoint

•Body weight, absolute change (kg)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05965908
Org study IDLiraglutide Polycystic Ovary

Timeline

Milestones

Study first posted2023-07-28actual
Study start2024-01-30actual
Primary completion2025-03-30actual
Study completion2025-03-30actual
Last update posted2026-03-06actual

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Obesity / overweightPCOSReproductive / infertility

Eligibility

Who can enroll

Minimum age20 Years
Maximum age40 Years
SexFemale
Healthy volunteersNot accepted

Inclusion criteria

•aged between 20 and 45 years
•PCO

Exclusion criteria

1. congenital adrenal hyperplasia

2. poorly controlled thyroid disease

3. Taking antidiabetic drugs which can affect insulin resistance

4. chronic kidney disease and history of recurrent urinary tract infections

5. liver dysfunction

6. documented use of oral hormonal contraceptives and hormone-releasing implants

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Weight & body composition

1 endpoint
Primary/protocol endpoint

Body weight loss

Time frame:1 months

Body weight, absolute change (kg)

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.